Fas´ Favourites from the CYTX-Past

Fas´ Favourites from the CYTX-Past (5)

I selected some articles which I wrote in the past- mainly from the 2011-2013 time period- which I still think are worth reading and which still raises the question mark- what went wrong?

IP issues with human body material and possibly the device? i.e. Celution. many speculations can be made- I still have an urge to find out the truth, but it is diminishing every day, since simply life goes on.

If you are bored and have nothing better to do- have a go at the following articles -

Sunday, 21 February 2016 23:52

Good news from Naples Italy

Written by
A subscriber to the Site had an interesting find of an article published in the Journal of Surgical Research, describing the placebo controlled clinical study of PAD (Peripheral Arterial Disease) patients with chronic ulcers treated with ADRCs from Celution. By my assessment this study is one of several European Celution device based clinical studies, which culminated in Cytori receiving market authorization (added claim to Celution for intended use of: therapy against chronic wounds- reported August 2012). As described in my other article: Another backdoor Slider,  EU regulations allow the device pathway for same day surgical and AUTOLOGOUS procedures, whereby the extracted cells remain property of the patient and ONLY can be used for this SAME patient as per the "Placed on the Market" principle.  This article is presented in "key elements" style instead of my usual long stories to keep our focus on the facts-  
Wednesday, 19 February 2014 07:47

The One that got away

Written by
If there is one thing that MDs and scientists who briefly experiment with fat cells agree upon with their colleagues who devote most of their lives studying these cells than it would be - yes- they seem to improve blood flow nicely. But why that is, has never really been all that clear. When Zuk et al plated the approx. 2% of plastic adherent SVF back in 2001/2 they apparently also did not know, which was evidenced approx. 4 years later in 2006, when UCLA  and Pittsburgh scientists battled in court with the ownership of the invention of the stromal part in SVF at stake. Pittsburgh won that battle, since they could produce a laboratory piece of paper with the handwritten note "Mesenchymal cell?" on it and Judge Consuela Marshall decided to become a free-lance scientist by suggesting that the MSCs must have travelled to the fat from the marrow and just changed properties slightly due to their new environment. Escaping "patent profanity"- patent lawyers call that. Neat story, but nowadays we know better thanks to the monumental work of Dr. Arnold Caplan from 2011- The Mesenchymal Stem Cell- an Injury Drugstore- which you can download at the bottom of this article.
On July 27 2010, Cytori surprised its investors by announcing that approval was received (together with breast augmentation and re-construction) for: The delivery of the Celution(R) System cellular output to facilitate healing of rectal and vaginal fistulas (wounds) resulting from Crohn's disease, the first stem cell-based approval in Europe for this condition. Up to that day, a coincidental statement by Chris Calhoun, CEO on the treatment of some patients with this disorder, was subsequently corrected by the legal department "as a slip of the tongue". This article will try to shed some light on this "mystery" approval and will explain the aspects of the condition.
Page 1 of 2

Copyright Information

Copyright Fas Kuiters © 2019-2020 raccoon-lodge.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.